Bemarituzumab is a first-in-class, humanized, isoform-selective monoclonal antibody targeting FGFR2b, designed to block FGF ligand binding and activation of FGFR2b, thereby inhibiting multiple downstream oncogenic signaling pathways and potentially delaying cancer progression; it is currently under development for the treatment of gastric and gastroesophageal junction (GEJ) cancers with FGFR2b overexpression, and its potential application in other FGFR2b-overexpressing tumors is also being evaluated.